1.Name and nature of the subject matter (if preferred shares, 
 the terms and conditions of issuance shall also be indicated, 
 e.g.dividend yield):
45,000,000 common stock shares of Diamond Biotech Investment Ltd.
2.Date of occurrence of the event:2014/08/14
3.Volume, unit price, and total monetary amount of the transaction:
Volume:45,000,000 shares
Unit price:NT$10 per share
total monetary:NT$450,000,000
4.Counterpart to the trade and its relationship to the Company 
  (if the trading counterpart is a natural person and furthermore 
  is not an actual related party of the Company, the name of the 
  trading counterpart is not required to be disclosed):
Counterpart is Diamond Biotech Investment Ltd.
The counterpart to the trade is a related party
5.Where the counterpart to the trade is an actual related party,
  a public announcement shall also be made of the reason for choosing 
  the related party as trading counterpart and the identity of the
  previous owner (including its relationship with the company and the 
  trading counterpart), price of transfer, and date of acquisition:
The only reason for participating in this trade is for
the counterpart's issuance of common stock share for cash
capital increase
6.Where a person who owned the property within the past five years
  has been an actual related person of the company, a public
  announcement shall also include the dates and prices of 
  acquisition and disposal by the related person and the 
  person¡¦s relationship to the company at those times:N/A
7.Matters related to the creditor's rights currently being disposed 
  of (including types of collateral of the disposed creditor's rights;
  if the creditor's rights are creditor's rights toward a related 
  person, the name of the related person and the book amount of the 
  creditor's rights toward such related person currently being 
  disposed of must also be announced):N/A
8.Anticipated profit or loss from the disposal (not applicable in 
  cases of acquisition of securities) (where originally deferred, the 
  status or recognition shall be stated and explained):N/A
9.Terms of delivery or payment (including payment period and 
  monetary amount), restrictive covenants in the contract, and 
  other important stipulations:Lump sum payment
10.The manner in which the current transaction was decided, the 
   reference basis for the decision on price, and the decision-making
   department:
The price is referred to an independent CPA's evaluation report
approved by the Board.
11.Current cumulative volume, amount, and shareholding percentage
   of holdings of the security being traded (including the current
   trade) and status of any restriction of rights (e.g.pledges):
Volume:80,000,000 shares
Total monetary:NT$800,000,000
ownership:10%
Restricted right situation:stock pledge 35,000,000 shares
12.Current ratio of long or short term securities investment 
   (including the current trade) to the total assets and shareholder's 
   equity as shown in the most recent financial statement and the
   operating capital as shown in the most recent financial statement:
to total assets ratio:1.58%
to shareholder's equity:1.93%
operating capital:N/A
13.Broker and broker's fee:N/A
14.Concrete purpose or use of the acquisition or disposition:Long term 
investment
15.Net worth per share of company underlying securities acquired 
   or disposed of:NT$9.76 per share
16.Do the directors have any objection to the present transaction?:None
17.Has the CPA issued an opinion on the unreasonableness of the price 
   of the current transaction?:None
18.Any other matters that need to be specified:None
distributed by